Renerve Ltd

Renerve Ltd

RNV · AU · Healthcare / Biotechnology

0.083AUD-0.00 (-1.19%)

Price History

Full chart

Market Stats

Previous Close0.084
Open0.083
Day Range0.083 – 0.083
52-Week Range0.068 – 0.22
Volume12.41K
Market Cap15.59M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
50-Day Avg0.0764
200-Day Avg0.0908

About

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Julian John Chick BSc (Hons)
  • Employees0
  • Headquarters157 Heidelberg Road, Northcote, VIC, Australia, 3070, Australia
  • Websitehttps://renerve.com.au

Leadership

  • Dr. Julian John Chick BSc (Hons)CEO & Executive Director · b. 1969
  • Mr. David Lilja CTA, M.B.A.CFO & Company Secretary
  • Dr. Alex Adamides FRACS, M.D.Chief Medical Officer & Member of Scientific Advisory Board

Financials

Income Statement

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue578.17K128.49K177.37K271.71K510.36K
Growth (%)--77.78%+38.04%+53.18%+87.83%
Cost of Revenue--62327.04K239.03K
Gross Profit578.17K128.49K176.75K244.67K271.32K
Gross Margin100.00%100.00%99.65%90.05%53.16%
Operating Expense2.33M2.32M3.29M4.70M6.79M
Operating Income-1.76M-2.20M-3.12M-4.45M-6.52M
Operating Margin-303.71%-1709.17%-1756.95%-1639.23%-1276.81%
EBITDA--1.65M-2.54M-3.44M-5.45M
EBITDA Margin--1284.16%-1434.47%-1265.46%-1068.10%
Net Income-1.76M-1.80M-2.98M-3.73M-5.57M
Net Income Margin-303.97%-1403.39%-1682.86%-1374.24%-1091.87%
R&D1.04M297.80K771.47K1.00M1.36M
R&D as % of Total Revenue179.79%231.76%434.94%368.32%266.38%
Interest Expense1.49K6.96K290.25K249.46K11.11K
Interest Expense % of Total Revenue0.26%5.42%163.64%91.81%2.18%

Balance Sheet

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets007.92M6.19M4.53M
Total Liabilities00503.03K998.87K1.36M
Total Equity007.42M5.20M3.18M
Cash--7.49M4.75M1.49M

Cash Flow

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Financing Cash Flow1.52M2.00M818.71K7.09M2.76M
Capital Expenditure115.89K45.84K4.98K65.30K147.38K
Free Cash Flow-1.98M-1.52M-2.30M-3.05M-5.95M

Key Statistics & Ratios

Market Cap15.59M
Enterprise Value10.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales30.56
Price / Book3.82
EPS-0.04
Book Value0.018
Revenue (TTM)510.36K
Gross Profit (TTM)271.32K
EBITDA-6.49M
Profit Margin0.00%
Operating Margin-1007.00%
Return on Equity-133.13%
Return on Assets-75.92%
Shares Outstanding173.28M
Shares Float92.76M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%